Benefits of Lilly's diabetes candidate tirzepatide aren't better than other diabetes drugs, says watchdog ICER
Eli Lilly’s tirzepatide — the type 2 diabetes candidate and Trulicity’s heir apparent, projected to be a megablockbuster drug within the next five years — has been waiting on the FDA to give it the OK. Yet according to cost watchdog ICER, there is still some doubt about just how useful it can be to patients when compared to top rivals.
The Institute for Clinical and Economic Review released its report on the drug candidate earlier today, giving evidence for the drug a “B+” rating and saying “the evidence provides high certainty that tirzepatide delivers at least a small net health benefit when added to background therapy, with the possibility of a substantial net health benefit.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
